{"id":"onartuzumab-metmab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Onartuzumab acts as a one-armed antibody (half-antibody) that selectively binds to the extracellular domain of MET and prevents HGF from activating MET signaling. This blocks downstream pathways including PI3K/AKT and MAPK/ERK that promote cell proliferation, survival, and metastasis in MET-dependent cancers. By inhibiting HGF-MET interaction, the drug aims to overcome resistance mechanisms in tumors with elevated MET expression or activation.","oneSentence":"Onartuzumab is a monoclonal antibody that blocks hepatocyte growth factor (HGF) binding to the MET receptor, inhibiting MET-driven tumor growth and survival signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:19.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer (NSCLC) in combination with erlotinib"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT02488330","phase":"PHASE3","title":"An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-27","conditions":"Solid Tumor","enrollment":12},{"nctId":"NCT01632228","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-06-29","conditions":"Glioblastoma","enrollment":135},{"nctId":"NCT01418222","phase":"PHASE2","title":"FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-09-14","conditions":"Colorectal Cancer","enrollment":194},{"nctId":"NCT01068977","phase":"PHASE1","title":"A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-08","conditions":"Solid Cancers","enrollment":44},{"nctId":"NCT00854308","phase":"PHASE2","title":"A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-04","conditions":"Non-Small Cell Lung Cancer","enrollment":137},{"nctId":"NCT02031731","phase":"PHASE1","title":"The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-13","conditions":"Neoplasms","enrollment":30},{"nctId":"NCT02031744","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-22","conditions":"Non-Small Cell Lung Cancer","enrollment":530},{"nctId":"NCT01186991","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-03","conditions":"Breast Cancer","enrollment":185},{"nctId":"NCT01887886","phase":"PHASE3","title":"A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-12","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":10},{"nctId":"NCT01897038","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Carcinoma, Hepatocellular","enrollment":9},{"nctId":"NCT01974258","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2014-02","conditions":"Neoplasms","enrollment":""},{"nctId":"NCT01662869","phase":"PHASE3","title":"A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-11","conditions":"Gastric Cancer","enrollment":564},{"nctId":"NCT01456325","phase":"PHASE3","title":"A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-01","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":494},{"nctId":"NCT01496742","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-04","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":259},{"nctId":"NCT01519804","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-04","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":108},{"nctId":"NCT01590719","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-07","conditions":"Gastric Cancer","enrollment":123},{"nctId":"NCT02044601","phase":"PHASE1, PHASE2","title":"Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-06","conditions":"Lung Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RO5490258"],"phase":"phase_3","status":"active","brandName":"Onartuzumab (MetMab)","genericName":"Onartuzumab (MetMab)","companyName":"Genentech, Inc.","companyId":"genentech-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Onartuzumab is a monoclonal antibody that blocks hepatocyte growth factor (HGF) binding to the MET receptor, inhibiting MET-driven tumor growth and survival signaling. Used for Metastatic non-small cell lung cancer (NSCLC) in combination with erlotinib, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}